NDAQ:SNGX - Post Discussion
Soligenix Inc
> Soligenix Granted Orphan Drug Designation for the Prevention
Post by
whytestocks on Apr 15, 2024 10:15am
Soligenix Granted Orphan Drug Designation for the Prevention
Breaking News: $SNGX Soligenix Granted Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection by FDA2024-04-15 08:01:00 ET DENVER, Colo., Apr 15, 2024 ( 247marketnews.com )- Soligenix, Inc. (NASDAQ: SNGX ) stated that the United States Food and Drug Administration’s Office of Orphan Products Development granted orphan drug designation to the active ingredient in MarVax, the...
SNGX - Soligenix Granted Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection by FDA
Be the first to comment on this post